Search
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigationalThis approval was based on favorable results obtained from the phase III APPL-PNH and APPOINT-PNH studies, where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor
Categories: Compounds used in a research, industrial, or household settingHydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.
Synonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineProducts: Hydroxycarbamid 1A Pharma 100 mg - Filmtabletten, Hydroxycarbamid 1A Pharma 1000 mg - FilmtablettenVelpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune … It is also currently the most potent HCV antiviral medication on the market with a sustained virologic response (SVR) after 12 weeks of therapy of 93-99% depending on genotype and level of cirrhosis and
Fexinidazole
go.drugbank.com/drugs/DB12265ApprovedTransmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage that progresses to a second (meningoencephalitic) stage in which patients experience progressively … [A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021.
Ustekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalUstekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. … L52830] and Wezlana [L52073] in Canada, and Uzpruvo in the EU.
Products: Stelara Solution for Injection in Pre-Filled Syringe 90 mg/1 mL, STELARA 90MG/1ML SOLUTION FOR INJECTION IN PREFILLED SYRINGEBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalBinimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib]. … [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexMethylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalIt is also a weak CYP2D6 inhibitor. FDA approved in 2008. … Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigationalpegcetacoplan], a novel inhibitor of C3. … [A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis.
Simoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedIt is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system. … Simoctocog alfa is a fourth-generation BDD FVIII product made in the human embryonic kidney (HEK) cell line.
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigationalbevacizumab a therapeutic role in both oncology and ophthalmology. … [A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target.
Categories: Complex MixturesSynonyms: Bei Fa Zhu Dankang